References
- Elias L, Portlock C S, Rosenberg S A. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 1978; 42: 1705–1710
- Fisher R I, Miller T P, Dana B W, Jones S E, Coltman C A, Dahlberg S, et al. Southwest Oncology Group clinical trials for intermediate and high-grade non-Hodgkin's lymphoma. Semin Hematol 1987; 24: 21–25
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 324: 1002–1006
- Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. Two weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of DSHNHL. Blood 2004; 104: 634–641
- Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
- Demiden A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes aB cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
- Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932
- Vose J M, Link B K, Grossbard M L, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
- The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
- Kaplan E l, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–282
- Habermann T M, Weller E A, Morrison V A, Cassileth P A, Cohn J B, Dakhil S R, et al. Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102: 8
- Pfreundschuh M G, Trumper L, Ma D, Österborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients < 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab early stopping after the first interim analysis. Proc ASCO 2004; 23: 6500a